MesoAI

MesoAI, based in the US, develops advanced artificial intelligence solutions focused on enhancing healthcare delivery and patient management through innovative technology. Founded in 2022, MesoAI creates AI-driven solutions for the healthcare sector. The company has received USD 200,000 in pre-seed funding from Antler, with its most recent deal occurring on March 7, 2025. The firm operates primarily in the US, with a growing presence in North America and Europe.

Meso AI specializes in advanced artificial intelligence solutions tailored for the healthcare and wellness sectors. Their core product offerings include AI-driven tools that optimize patient management, enhance diagnostic accuracy, and streamline operational efficiencies within healthcare facilities. These tools are designed to address critical pain points, such as high patient volumes, diagnostic errors, and administrative burdens, ultimately improving patient outcomes and operational workflows. Meso AI’s products are utilized by hospitals, clinics, and healthcare providers primarily across North America and Europe, with a growing presence in Asian markets.

Their client base includes both large healthcare networks and smaller independent practices, catering to a diverse range of end-users, including healthcare professionals and patients. Meso AI generates revenue through a subscription-based model that allows healthcare providers to access their suite of AI tools and services. Clients typically engage in annual contracts that provide tiered pricing based on the size of the organization and the specific features utilized, ensuring flexibility for various budgetary constraints. For example, a mid-sized hospital might enter a partnership that includes access to Meso AI's flagship diagnostic tool, enabling real-time data analysis and decision support for clinical staff.

Additional revenue may stem from consulting services that assist clients in integrating AI solutions into their existing systems. The company’s transaction structure emphasizes long-term relationships with clients, offering ongoing support and updates as part of their service agreements. MesoAI plans to enhance its product offerings by developing new AI tools aimed at improving patient diagnostics and management. The company is targeting expansion into Asian markets by the end of 2025.

The recent funding of USD 200,000 will be utilized to support the design and launch of these upcoming products, facilitating their entry into new geographic regions.